首页> 外国专利> METHOD OF PREDICTING WHETHER A KIDNEY TRANSPLANT RECIPIENT IS AT RISK OF HAVING ALLOGRAFT LOSS

METHOD OF PREDICTING WHETHER A KIDNEY TRANSPLANT RECIPIENT IS AT RISK OF HAVING ALLOGRAFT LOSS

机译:预测肾移植受体是否有具有同种异体移植损失的风险的方法

摘要

Organ transplantation is currently recognised as the treatment of choice for patients with end-stage renal disease (ESRD), which is an underestimated but increasing burden worldwide. Despite the pressing need for improving patients risk stratification raised by transplant societies as well as regulatory agencies, no risk-stratification system exists that adequately predicts transplant patients' individual risk of allograft loss. This currently represents a limitation for improving patient management, as well as for defining early surrogate end points for clinical trials and development of pharmaceutical agents. The inventors now report the development and validation of an integrative risk prediction score to predict kidney allograft survival of individual patients (NCT03474003). The iBox risk prediction score is the first integrative system validated in several independent populations from Europe & North America as well as across 3 clinical trials (NCT01079143, Eudra CT2007-003213-13, NCT01873157) covering distinct clinical scenarios. In particular, the advantages brought by the iBox risk prediction score are i) improved discrimination performance by combining traditional prognostic factors with mechanistically informed parameters, ii) outperformance when compared with currently existing scoring systems, iii) generalisability when assessed in geographically distinct cohorts from Europe and North America, iv) transportability at different times of evaluation post-transplant, v) performance in a variety of clinical scenarios including clinical trials and vi) readily accessible to clinicians and patients by an online tool for patient risk calculation. Thus, the present invention relates to a method of predicting whether a kidney transplant recipient is at risk of having allograft loss by implementing the iBox risk prediction score.
机译:器官移植目前被认为是对末期肾病(ESRD)患者的选择的治疗,这是一个低估但在全世界的负担增加。尽管迫切需要改善移植社会以及监管机构提出的患者风险分层,但没有风险分层系统存在充分预测移植患者的同种异体移植损失风险。这目前代表改善患者管理的限制,以及定义用于临床试验和制药剂的发育的早期替代终点。本发明人现在报告了综合风险预测得分的开发和验证,以预测个体患者的肾同种异体移植物存活(NCT03474003)。 IBox风险预测得分是在欧洲和北美的几个独立群体中验证的第一个综合系统,以及3种临床试验(NCT01079143,eudra CT2007-003213-13,NCT01873157)涵盖了不同的临床情景。特别是,IBox风险预测得分带来的优点是通过将传统的预后因素与机械上通知参数,ii)与当前现有的评分系统相比,在从欧洲的地理上不同的群组中评估时相比,改善了传统的预后因素。和北美,IV)在移植后的不同时间的可运输性,v)在各种临床情景中的性能,包括临床试验和vi)通过临床医生和患者通过在线工具进行患者风险计算的临床医生和患者。因此,本发明涉及通过实现IBox风险预测得分来预测肾移植接收者是否有具有同种异体移植损耗的风险的方法。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号